Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anlotinib + Cadonilimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anlotinib | AL3818|AL-3818|AL 3818 | FGFR Inhibitor (Pan) 26 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 RET Inhibitor 52 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 | Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, FGFR1-4, PDGFRA/B, KIT, and RET, which may inhibit angiogenesis and tumor cell growth (PMID: 27716285, PMID: 32547218, PMID: 32724339). | |
Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|